Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : LLY save search
Lilly to Acquire Sigilon Therapeutics
Published: 2023-06-29 (Crawled : 12:00) - biospace.com/
SGTX | $22.47 -2.56% 0.0% 0
|
Health Technology
|
| O: 582.44%
H: 4.4%
C: -21.14%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.08%
H: 1.47%
C: 1.18%
acquire therapeutics
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies
Published: 2023-10-03 (Crawled : 12:00) - biospace.com/
PNT | $13.68 2.63% 0.15% 0
|
|
| O: 85.39%
H: 0.81%
C: 0.41%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
biopharma acquire
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
Published: 2022-10-18 (Crawled : 11:00) - prnewswire.com
PPRUF | News | $359.318 37.56% 490
|
Consumer Non-Durables
|
| O: 2.47%
H: 0.06%
C: -5.34%
PPRUY | News | $36.19 -0.11% 360K
|
Manufacturing
|
| O: 2.62%
H: 0.0%
C: -1.01%
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.41%
H: 0.36%
C: 0.27%
AKUS | $13.29 1.07% 3.46%
|
Health Technology
|
| O: 73.76%
H: 1.83%
C: 0.61%
acquire
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease
Published: 2021-08-31 (Crawled : 12:00) - globenewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.2%
H: 0.3%
C: -1.73%
ACIU | $2.45 0.0% 250K
|
Health Technology
|
| O: 71.82%
H: 5.0%
C: -32.31%
disease alzheimer positive results antibody semorinemab alzheimer’s alzheimer's disease alzheimer's
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
Published: 2023-10-03 (Crawled : 10:00) - globenewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
ALXO | $16.08 10.97% 9.89% 2M
|
Commercial Services
|
| O: 68.19%
H: 2.84%
C: -7.17%
aspen-06 positive cancer treatment trial results
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
Published: 2022-12-22 (Crawled : 12:00) - globenewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.19%
H: 0.66%
C: -0.55%
PRQR | $1.92 -4.0% -4.17% 200K
|
Health Technology
|
| O: 64.85%
H: 13.97%
C: -0.74%
axiomer conference platform
Lilly and ProQR to Expand RNA Editing Collaboration
Published: 2022-12-22 (Crawled : 12:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.19%
H: 0.66%
C: -0.55%
PRQR | $1.92 -4.0% -4.17% 200K
|
Health Technology
|
| O: 64.85%
H: 13.97%
C: -0.74%
collaboration
Lilly and ProQR to Expand RNA Editing CollaborationNew agreement supports the discovery and development of additional assets directed toward high conviction targets utilizing ProQR’s Axiomer technology
Published: 2022-12-22 (Crawled : 13:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.19%
H: 0.66%
C: -0.55%
PRQR | $1.92 -4.0% -4.17% 200K
|
Health Technology
|
| O: 64.85%
H: 13.97%
C: -0.74%
axiomer technology agreement
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform
Published: 2021-12-13 (Crawled : 12:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 1.27%
H: 0.0%
C: 0.0%
FHTX | $5.76 -4.48% -4.69% 130K
|
Health Technology
|
| O: 51.84%
H: 0.0%
C: 0.0%
control collaboration platform
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
Published: 2022-04-11 (Crawled : 12:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
VERU | $1.165 -7.17% -7.73% 2.5M
|
Health Technology
|
| O: 37.7%
H: 143.24%
C: 105.01%
covid-19 drug sabizabulin phase 3
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 11:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
VERU | $1.165 -7.17% -7.73% 2.5M
|
Health Technology
|
| O: 20.75%
H: 0.0%
C: 0.0%
covid-19 fda sabizabulin authorization positive phase 3 emergency use authorization
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.71%
H: 0.0%
C: 0.0%
ORIC | $9.79 3.6% 3.47% 510K
|
Health Technology
|
| O: -2.81%
H: 1.54%
C: -3.57%
NRIX 1 d | $14.1 -3.75% -3.9% 970K
|
Health Technology
|
| O: 18.35%
H: 1.98%
C: -5.88%
therapeutics
Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases
Published: 2021-02-18 (Crawled : 12:11) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.56%
H: 0.06%
C: -2.04%
RIGL | $1.115 -2.19% -2.24% 580K
|
Health Technology
|
| O: 17.44%
H: 3.38%
C: -10.53%
disease treatment neurodegenerative collaboration potential
Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19
Published: 2021-04-13 (Crawled : 12:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.35%
H: 1.36%
C: 0.75%
RIGL | $1.115 -2.19% -2.24% 580K
|
Health Technology
|
| O: 13.27%
H: 5.14%
C: 3.14%
covid phase 2 positive topline trial
Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park
Published: 2023-01-24 (Crawled : 12:00) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 12.34%
H: 0.0%
C: -9.9%
research
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published: 2022-06-06 (Crawled : 11:00) - globenewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
VERU | $1.165 -7.17% -7.73% 2.5M
|
Health Technology
|
| O: 10.2%
H: 0.0%
C: 0.0%
sabizabulin trial presentation positive cancer phase 2b prostate cancer
AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta
Published: 2021-06-02 (Crawled : 12:00) - globenewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.3%
H: 0.96%
C: 0.06%
ACIU | $2.45 0.0% 250K
|
Health Technology
|
| O: 9.89%
H: 2.4%
C: -9.71%
disease alzheimer vaccine aci-24 alzheimer’s alzheimer's disease alzheimer's
Veru Announces Date for FDA Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-09-07 (Crawled : 18:00) - globenewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 0.64%
H: 1.18%
C: 0.92%
VERU | $1.165 -7.17% -7.73% 2.5M
|
Health Technology
|
| O: 9.6%
H: 3.38%
C: -28.02%
covid-19 fda risk sabizabulin meeting respiratory review authorization
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
Published: 2023-07-17 (Crawled : 13:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: -0.0%
H: 0.26%
C: -0.51%
SGMO | $0.513 -5.35% -5.65% 1.2M
|
Health Technology
|
| O: 9.3%
H: 0.71%
C: -6.38%
wholly research therapeutics agreement
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC
Published: 2022-06-22 (Crawled : 12:00) - investor.aveooncology.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 1.31%
H: 0.0%
C: 0.0%
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 8.59%
H: 9.93%
C: 5.88%
erbitux america collaboration trial agreement
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.